Literature DB >> 9701344

Exacerbation of ischemic brain damage by localized striatal injection of interleukin-1beta in the rat.

R P Stroemer1, N J Rothwell.   

Abstract

Interleukin-1beta (IL-1beta) has been implicated in ischemic brain damage. The site of action of IL-1beta in such damage is not known, but we have demonstrated previously that injection of the interleukin-1 receptor antagonist (IL-1ra) in the striatum but not the cortex of rats inhibits damage caused by permanent middle cerebral artery occlusion. The present study investigated the site of action of IL-1beta on ischemic damage by examining the effects of intracerebroventricular, striatal, or cortical injection of recombinant IL-1beta at the onset of permanent middle cerebral artery occlusion in the rat. Intracerebroventricular injection of IL-1beta (2.5 ng) significantly increased infarct volume in the striatum (35%, P < 0.0001) and in the cortex (44%, P < 0.0001) compared with vehicle treatment. Direct injection of IL-1beta into the striatum also increased infarct volume in both the striatum (36%, P < 0.0001) and the cortex (38%, P < 0.0001), whereas injection of IL-1beta into the cortex failed to affect infarct volume in either the striatum or the cortex. Cortical injection of a higher dose of IL-1beta (20 ng) also failed to affect ischemic damage in either the striatum or the cortex. Injection of IL-1beta into the striatum contralateral to the infarction had no effect on striatal damage in the ischemic hemisphere, but did increase cortical damage by 18% (P < 0.0001). In separate groups of animals, IL-1beta (2.5 ng) was injected into either the striatum or the cortex, and body temperature was recorded continuously in conscious free-moving animals by remote telemetry. Injection of IL-1beta at either site failed to influence body temperature, suggesting that exacerbation of brain damage by striatal injection of IL-1beta is not caused by effects on body temperature. These results imply that IL-1beta exacerbates ischemic damage by specific actions in the striatum where it can influence damage at distant sites in the cortex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701344     DOI: 10.1097/00004647-199808000-00003

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  44 in total

1.  Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor.

Authors:  Omar Touzani; Herve Boutin; Rosalind LeFeuvre; Lisa Parker; Andy Miller; Giamal Luheshi; Nancy Rothwell
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

Review 2.  Annual review prize lecture cytokines - killers in the brain?

Authors:  N J Rothwell
Journal:  J Physiol       Date:  1999-01-01       Impact factor: 5.182

3.  IL-1β down-regulates ADAMTS-13 mRNA expression in cells of the central nervous system.

Authors:  G Alkistis Frentzou; Claire Bradford; Kirsty A Harkness; Gail Haddock; M Nicola Woodroofe; Alison K Cross
Journal:  J Mol Neurosci       Date:  2011-07-06       Impact factor: 3.444

4.  Cortical cell death induced by IL-1 is mediated via actions in the hypothalamus of the rat.

Authors:  S M Allan; L C Parker; B Collins; R Davies; G N Luheshi; N J Rothwell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

5.  Regional TNFα mapping in the brain reveals the striatum as a neuroinflammatory target after ventricular fibrillation cardiac arrest in rats.

Authors:  Andreas Janata; Ingrid A M Magnet; Thomas Uray; Jason P Stezoski; Keri Janesko-Feldman; Samuel A Tisherman; Patrick M Kochanek; Tomas Drabek
Journal:  Resuscitation       Date:  2014-02-12       Impact factor: 5.262

6.  Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat.

Authors:  Nicholas J Mulcahy; Jerard Ross; Nancy J Rothwell; Sarah A Loddick
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Change in blood-brain barrier permeability during pediatric diabetic ketoacidosis treatment.

Authors:  Monica S Vavilala; Todd L Richards; Joan S Roberts; Harvey Chiu; Catherine Pihoker; Heidi Bradford; Kristina Deeter; Ken I Marro; Dennis Shaw
Journal:  Pediatr Crit Care Med       Date:  2010-05       Impact factor: 3.624

8.  The acute phase response and soman-induced status epilepticus: temporal, regional and cellular changes in rat brain cytokine concentrations.

Authors:  Erik A Johnson; Robert K Kan
Journal:  J Neuroinflammation       Date:  2010-07-22       Impact factor: 8.322

9.  Following experimental stroke, the recovering brain is vulnerable to lipoxygenase-dependent semaphorin signaling.

Authors:  Anton Pekcec; Kazim Yigitkanli; Joo Eun Jung; Stefanie Pallast; Changhong Xing; Alexander Antipenko; Maria Minchenko; Dimitar B Nikolov; Theodore R Holman; Eng H Lo; Klaus van Leyen
Journal:  FASEB J       Date:  2012-10-15       Impact factor: 5.191

Review 10.  Hypoxic-ischemic encephalopathy in the term infant.

Authors:  Ali Fatemi; Mary Ann Wilson; Michael V Johnston
Journal:  Clin Perinatol       Date:  2009-12       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.